Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Abivax SA Sponsored ADR ABVX

Healthcare  —  Biotechnology
91.06 (3.81) (4.02%) as of 25 Sep
Market cap
$8.2B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Abivax SA Sponsored ADR (ABVX) Business Profile

Updated before January 2025

Company Overview

Abivax SA Sponsored ADR (ABVX) is a clinical-stage biotechnology company headquartered in Paris, France. Founded in 2013, the company focuses on developing innovative therapies to treat inflammatory diseases, viral infections, and cancer. Abivax is led by a team of seasoned professionals, including its CEO, Professor Hartmut Ehrlich, who has extensive experience in the pharmaceutical and biotechnology industries. The company is listed on the NASDAQ under the ticker symbol ABVX and has gained recognition for its cutting-edge research and development efforts.

Core Business Segments

Inflammatory Diseases

Abivax’s primary focus is on developing treatments for chronic inflammatory diseases. The company’s lead product candidate, obefazimod (ABX464), is a first-in-class oral small molecule that has shown promise in treating ulcerative colitis and Crohn’s disease. Obefazimod works by modulating the immune response and reducing inflammation, offering a potential breakthrough for patients with these debilitating conditions.

Viral Infections

Abivax is also committed to addressing unmet medical needs in the field of viral infections. The company has developed ABX196, an immune enhancer that is being investigated for its potential to treat chronic hepatitis B. This product leverages Abivax’s expertise in immunology to provide innovative solutions for viral diseases.

Oncology

In the oncology segment, Abivax is exploring the use of its proprietary technology platforms to develop novel cancer therapies. While this area is still in the early stages of development, the company is actively pursuing partnerships and collaborations to accelerate progress.

Business Model

Abivax operates on a research-driven business model that integrates cutting-edge science with a focus on addressing unmet medical needs. The company generates revenue through licensing agreements, partnerships, and milestone payments from its collaborators. By leveraging its proprietary technology platforms, Abivax aims to develop high-value therapies that can be commercialized globally. The company also invests heavily in clinical trials to ensure the safety and efficacy of its product candidates.

Strategic Direction

Abivax has a clear strategic vision aimed at achieving long-term growth and sustainability. The company’s primary goals include:

  • Advancing Clinical Development: Abivax is focused on advancing obefazimod through late-stage clinical trials for ulcerative colitis and Crohn’s disease. The company aims to secure regulatory approvals and bring this innovative therapy to market.
  • Expanding Therapeutic Areas: In addition to inflammatory diseases, Abivax plans to explore new therapeutic areas, including oncology and viral infections, to diversify its product portfolio.
  • Sustainability Goals: Abivax is committed to minimizing its environmental impact by adopting sustainable practices in its research and manufacturing processes.
  • Global Expansion: The company aims to establish a strong presence in key markets, including the United States, Europe, and Asia, through strategic partnerships and collaborations.

Competitive Landscape

Abivax operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • AbbVie Inc.: Known for its blockbuster drug Humira, AbbVie is a major player in the inflammatory disease market.
  • Gilead Sciences: A leader in antiviral therapies, Gilead competes with Abivax in the field of hepatitis B treatment.
  • Takeda Pharmaceutical Company: Takeda’s focus on gastroenterology and inflammatory diseases makes it a direct competitor to Abivax.
  • Biogen: With a strong presence in immunology and neurology, Biogen poses competition in the inflammatory disease segment.

Despite the competition, Abivax differentiates itself through its innovative approach and focus on first-in-class therapies.

Risk Factors

Abivax faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The company is subject to stringent regulatory requirements, and delays in obtaining approvals could affect its product launch timelines.
  • Market Dependence: Abivax’s reliance on a limited number of product candidates increases its vulnerability to market fluctuations.
  • Supply Chain Disruptions: Any disruptions in the supply chain could delay clinical trials and product manufacturing.
  • Competition: Intense competition in the biotechnology sector could impact Abivax’s market share and pricing power.
  • Financial Risks: As a clinical-stage company, Abivax relies on external funding and may face challenges in securing additional capital.

Recent Developments

Abivax has made significant progress in recent months, including:

  • Clinical Trials: The company announced positive results from Phase 2b clinical trials of obefazimod for ulcerative colitis, paving the way for Phase 3 trials.
  • Partnerships: Abivax entered into a strategic collaboration with a leading pharmaceutical company to co-develop and commercialize obefazimod.
  • Funding: The company successfully raised capital through a public offering to support its clinical development programs.
  • Regulatory Milestones: Abivax received Fast Track designation from the FDA for obefazimod, highlighting its potential to address unmet medical needs.

Investment Considerations

Strengths

  • Innovative Pipeline: Abivax’s focus on first-in-class therapies positions it as a leader in the biotechnology sector.
  • Experienced Leadership: The company’s management team brings extensive expertise in drug development and commercialization.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance Abivax’s capabilities and market reach.
  • Regulatory Support: Fast Track designation and other regulatory milestones validate the potential of Abivax’s product candidates.

Risks

  • Clinical and Regulatory Uncertainty: The success of Abivax’s pipeline depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, Abivax relies on external funding, which may not always be readily available.
  • Market Competition: Intense competition from established players could impact Abivax’s market penetration.

Conclusion

Abivax SA Sponsored ADR is a promising biotechnology company with a strong focus on developing innovative therapies for inflammatory diseases, viral infections, and cancer. With a robust pipeline, experienced leadership, and strategic partnerships, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage companies before making investment decisions. Overall, Abivax’s commitment to addressing unmet medical needs and its strategic vision make it a compelling player in the biotechnology sector.